All news

Prometic makes Nabi hyper

Prometic makes Nabi hyper

By Gregory Roumeliotis

Nabi Biopharmaceuticals has obtained the exclusive rights to use a
plasma protein purification technology from ProMetic Life Sciences
in the large-scale development and manufacture of its hyperimmune
products, cutting production costs...

Biopharma causes Cambrex bleed

Biopharma causes Cambrex bleed

By Gregory Roumeliotis

Life sciences firm Cambrex has reported a $140.3m (€116.7m) loss in
Q4 as opposed to a profit of $4.9m in Q4 last year, hit by lower
long-term profitability projections for its Biopharma unit, as
biotech companies seem to lose their...

Investors show faith in Biopure

Investors show faith in Biopure

By Gregory Roumeliotis

Oxygen therapeutics company Biopure has announced another $3
million (€2.5 million) public offering to boost its working
capital, despite its major drug for humans, Hemopure, an artificial
blood product, being licensed only in South...

Follow us

Webinars

Headlines